Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma

The test is sequenced using Illumina high-throughput sequencers and accompanying kits. Conduct preliminary quality control on the samples, and the tumor cell content of the tissue samples shall not be less than 30%. Tissue DNA was extracted from tumor tissue samples according to the instructions of the QIAGEN DNA extraction kit. Samples qualified for quality control shall be arranged for further library construction. The extracted DNA samples were sequentially purified by fragment purification, terminal repair, splicing, fragment size selection, PCR amplification, product purification, library enrichment, and library product quality control. After qualified quality control, the constructed library was sequenced by Illumina matching kit. Bioinformatics analysis would be conducted.

Inclusion criteria

• willing to participate in the study and sign the informed consent
• age ≥18 years old
• researchers evaluated that it was suitable to participate in this translational study
• Endometrial cancer was confirmed histologically
• histopathological molecular classification was consistent with pMMR type and POLE wild type
• The tumor tissue obtained by operation was the primary lesion

Exclusion criteria

• Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection
• previously treated with KIF18A inhibitors
• researchers believed that the subjects were not suitable for the translational study for other reasons